FDA Approves First Interchangeable Biosimilar for Inflammatory Diseases
Cyltezo is first interchangeable monoclonal antibody for RA, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, chronic plaque psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.